Morgan Stanley reaffirmed an overweight rating on AbbVie, and Barclays raised its price objective on September 10, 2026.

The entities involved

• AbbVie →

  pharmaceutical company

  • MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
  • AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sun 13:48
• Morgan Stanley →

  U.S. investment bank

  • Financial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Mon 17:33
  • Goldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Mon 17:24
• Barclays →

  British bank

  • QinetiQ carried out share purchases and arranged for a share buyback execution on the London Stock Exchange.Mon 13:19
  • Financial institutions provided ratings on multiple companies on July 8, 2026, including Goldman Sachs reiterating Tesla as neutral, Barclays initiating Toast as overweight, and Bank of America rating Nvidia as a buy.Sun 14:53

Related events

• Barclays maintained Overweight rating and raised price target on August 29, 2025.Jun 7
• Morgan Stanley raised its price target and maintained an overweight rating for Wingstop.Jun 8
• Barclays reiterated an overweight rating on the stock of Brighthouse Financial.Jun 8
• Morgan Stanley reissued an overweight rating for Wynn Resorts, which was reported by MarketBeat.Sep 10
• Morgan Stanley lowered its rating for CAE Inc from equal weight to underweight on August 27, 2026.Aug 27